{
  "source": "PA-Notification-Filsuvez.txt",
  "chunks": [
    "UnitedHealthcare Pharmacy\nClinical Pharmacy Programs\nProgram Number 2025 P 1442-2\nProgram Prior Authorization/Notification\nMedication Filsuvez® (birch triterpenes) topical gel\nP&T Approval Date 4/2024, 4/2025\nEffective Date 7/1/2025\n1. Background:\nFilsuvea (birch triterpenes) topical gel is indicated for the treatment of wounds associated with\ndystrophic and junctional epidermolysis bullosa in adult and pediatric patients 6 months of age\nand older.\n2. Coverage Criteriaa:\nA. Initial Authorization\n1. Filsuvez will be approved based on all of the following criteria:\na. Patient is at least 6 months of age and older\n-AND-\nb. One of the following diagnoses:\n(1) Dystrophic epidermolysis bullosa (DEB)\n-OR-\n(2) Junctional epidermolysis bullosa (JEB)\n-AND-\nc. Patient is not receiving Filsuvez in combination with Vyjuvek (beremagene\ngeperpavec-svdt) on the same wound(s)\nAuthorization will be issued for 12 months.\n2. Reauthorization\na. Filsuvez will be approved based all of the following criteria:\n(1) Documentation of positive clinical response to therapy\n-AND-\n(2) Patient is not receiving Filsuvez in combination with Vyjuvek (beremagene\ngeperpavec-svdt) on the same wound(s)\n© 2025 UnitedHealthcare Services, Inc.\n1\nAuthorization will be issued for 12 months.\na State mandates may apply. Any federal regulatory requirements and the member specific\nbenefit plan coverage may also impact coverage criteria. Other policies and utilization\nmanagement programs may apply.\n3. Additional Clinical Rules:\n• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-\nauthorization based solely on previous claim/medication history, diagnosis codes (ICD-10)\nand/or claim logic. Use of automated approval and re-approval processes varies by program\nand/or therapeutic class.\n• Supply limits may be in place.\n4. References:\n1. Filsuvez [package insert]. Boston, MA: Chiesi Global Rare Diseases; May 2024.\nProgram Prior Authorization/Notification - Filsuvez (birch triterpenes)\nChange ",
    " limits may be in place.\n4. References:\n1. Filsuvez [package insert]. Boston, MA: Chiesi Global Rare Diseases; May 2024.\nProgram Prior Authorization/Notification - Filsuvez (birch triterpenes)\nChange Control\n4/2024 New program.\n4/2025 Annual review with no changes to criteria. Updated references.\n© 2025 UnitedHealthcare Services, Inc.\n2"
  ]
}